S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:CLSD - Clearside Biomedical Stock Price, Forecast & News

$2.15
-0.36 (-14.34 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$2.05
Now: $2.15
$2.47
50-Day Range
$2.10
MA: $2.81
$3.77
52-Week Range
$0.56
Now: $2.15
$4.13
Volume767,103 shs
Average Volume1.34 million shs
Market Capitalization$95.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.05
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30,000.00
Book Value$0.74 per share

Profitability

Net Income$-82,820,000.00
Net Margins-18,893.49%

Miscellaneous

Employees50
Market Cap$95.49 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.


Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical Inc (NASDAQ:CLSD) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.01. The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.05 million. Clearside Biomedical had a negative return on equity of 316.25% and a negative net margin of 18,893.49%. View Clearside Biomedical's Earnings History.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Clearside Biomedical.

What price target have analysts set for CLSD?

4 analysts have issued 12-month price objectives for Clearside Biomedical's shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Clearside Biomedical's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 109.3% from the stock's current price. View Analyst Price Targets for Clearside Biomedical.

What is the consensus analysts' recommendation for Clearside Biomedical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clearside Biomedical.

What are Wall Street analysts saying about Clearside Biomedical stock?

Here are some recent quotes from research analysts about Clearside Biomedical stock:
  • 1. According to Zacks Investment Research, "Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. " (1/29/2020)
  • 2. Wedbush analysts commented, "Our $69 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline and estimated year-end cash. We use the net present value of our revenue forecast through 2026, apply a 65% probability of success and a 2.5x price/sales multiple for luspatercept, and our year-end cash estimate of $7.49 to arrive at our price target. We use a 20% discount rate for the pipeline as it is above the marketed products discount rate due to development risks but within the typical range of 15-25% for products in development." (8/6/2019)

Has Clearside Biomedical been receiving favorable news coverage?

News coverage about CLSD stock has trended extremely negative on Thursday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Clearside Biomedical earned a news sentiment score of -4.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Clearside Biomedical.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 2,400,000 shares, an increase of 62.2% from the January 30th total of 1,480,000 shares. Based on an average trading volume of 1,250,000 shares, the short-interest ratio is presently 1.9 days. Currently, 7.5% of the company's shares are short sold. View Clearside Biomedical's Current Options Chain.

Who are some of Clearside Biomedical's key competitors?

What other stocks do shareholders of Clearside Biomedical own?

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the folowing people:
  • Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)
  • Mr. Charles A. Deignan, Chief Financial Officer (Age 55)
  • Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)
  • Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)
  • Mr. Rick McElheny, VP of Corp. Devel.

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.62%), Oxford Asset Management LLP (0.30%), Renaissance Technologies LLC (0.20%), Signaturefd LLC (0.13%), Virtu Financial LLC (0.12%) and Wedbush Securities Inc. (0.09%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Clay Thorp, Daniel H White, George M Lasezkay and Gerald D Cagle. View Institutional Ownership Trends for Clearside Biomedical.

Which institutional investors are selling Clearside Biomedical stock?

CLSD stock was sold by a variety of institutional investors in the last quarter, including Signaturefd LLC, Wedbush Securities Inc. and UBS Group AG. View Insider Buying and Selling for Clearside Biomedical.

Which institutional investors are buying Clearside Biomedical stock?

CLSD stock was bought by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Renaissance Technologies LLC, Virtu Financial LLC, Geode Capital Management LLC, Fred Alger Management LLC, Integrated Advisors Network LLC, Donald L. Hagan LLC and Game Plan Financial Advisors LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Clay Thorp, Daniel H White, George M Lasezkay and Gerald D Cagle. View Insider Buying and Selling for Clearside Biomedical.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $2.15.

How big of a company is Clearside Biomedical?

Clearside Biomedical has a market capitalization of $95.49 million and generates $30,000.00 in revenue each year. The company earns $-82,820,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.View Additional Information About Clearside Biomedical.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is http://www.clearsidebio.com/.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]


MarketBeat Community Rating for Clearside Biomedical (NASDAQ CLSD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  291 (Vote Outperform)
Underperform Votes:  242 (Vote Underperform)
Total Votes:  533
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel